BDKRB2 as a frequently amplified molecule has been observed in a range of cancers, including cervical cancer [10], triple-negative breast cancer [11], hepatocellular carcinoma (HCC) [12, 13], gastric cancer [14–16], colorectal cancer [17], prostate cancer [18], bladder cancer [19], head and neck squamous cell carcinomas [20], and chondrosarcoma [21]. Here, BDKRB2 is linked to hepatocellular carcinoma.